^
Association details:
| Biomarker: | MSH2 mutation + MSH6 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB004 - Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial
Published date:
04/09/2021
Excerpt:
Pts with mCRPC who progressed following ≥1 line of therapy and ImS+ were eligible. ImS+ was defined by ≥1 of the following: 1) mismatch repair deficient (MMRD) by immunohistochemistry (IHC); 2) DNA damage repair deficient (DDRD) excluding MMRD, detected by the UW-OncoPlex targeted exome sequencing assay...The overall CRR was 9/35 (26%, 95%CI 12-43%).... NIVO + IPI demonstrated significant activity in biomarker selected, pre-treated pts with mCRPC.
